関連する実験動画
Updated: Jul 14, 2026
16:46
A Novel Stretching Platform for Applications in Cell and Tissue Mechanobiology
Published on: June 3, 2014
動脈硬化性ヒト冠動脈のアルファ・アドレナージック収縮が増加した
1Departments of Cardiology and Pathophysiology (G.H.), Center of Internal Medicine, University of Essen, Germany. dbaum3@t-online.de
Circulation
|April 27, 1999
まとめ
アルファ-1 アドレナージック活性化は,健康な動脈の冠動脈の血流に影響を及ぼさないが,アルファ-2 アクティベーションは収縮を引き起こす. 動脈硬化症はこれらの効果を悪化させ,潜在的に心筋梗塞不全を引き起こします.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- 生理学 生理学とは
背景:
- アドレナージック活性化は,実験的な心筋動脈不全症に関連しています.
- 人体におけるアルファアドレナジック冠動脈収縮の役割は不明である.
- この研究では,ヒトの冠動脈における選択的なアルファアドレネルゲン受容体活性化を調査しています.
研究 の 目的:
- 人間の冠動脈血流 (CBF) への選択的なα1-およびα2-アドレナリン受容体活性化の影響を評価する.
- 冠動脈動脈硬化症がアルファアドレナジックアゴニストに対する反応に影響するかどうかを判断する.
- アルファアドレネルギー活性化によって心筋不全を引き起こす可能性を評価する.
主な方法:
- 39人の患者の冠動脈血流 (CBF) は,結合血管図とドップラー測定を用いて測定されました.
- 選択性アルファ1-アゴニスト (メトキサミン) とアルファ2-アゴニスト (BHT933) を増量投与した.
- 心筋乳酸の産生は,単一の冠動脈狭窄症の患者で評価されました.
主要な成果:
- アルファ1-アドレナージック活性化は,正常な冠動脈におけるCBFを変化させなかった.
- アルファ1およびアルファ2アドレナージ的活性化の両方が,冠動脈狭窄症の患者で,投与量に依存してCBFを減少させた.
- アルファ2-アドレナージック活性化により,乳酸塩の純産量が増加し,心筋不全が増加したことを示した.
結論:
- アルファ2-アドレナージック活性化は,正常な冠動脈のマイクロ血管収縮を引き起こします.
- アルファ1およびアルファ2アドレナジック活性化誘発の収縮は,両方が動脈硬化によって増幅されます.
- これらの効果は,冠動脈疾患の患者の心筋梗塞不全を早める可能性があります.
関連する概念動画
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...